US Stock MarketDetailed Quotes
BIVI BioVie
- 1.140
- -0.040-3.39%
Close Oct 14 16:00 ET
- 1.180
- +0.040+3.49%
Pre 09:08 ET
9.10MMarket Cap-156P/E (TTM)
1.205High1.120Low166.25KVolume1.200Open1.180Pre Close191.15KTurnover2.99%Turnover RatioLossP/E (Static)7.98MShares58.20052wk High0.59P/B6.34MFloat Cap1.04052wk Low--Dividend TTM5.56MShs Float460.977Historical High--Div YieldTTM7.20%Amplitude1.040Historical Low1.149Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
BioVie Stock Forum
BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin
BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin
BioVie Inc. (NASDAQ: BIVI) has received a Notice of Allowance from the USPTO for a patent application covering a novel liquid formulation of terlipressin acetate. This formulation demonstrates room-temperature stability for up to 24 months and can be packaged in a pre-filled syringe. The patent is expected to be listed in the Orange Book and supports Bi...
CARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) and accomp...
BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID
Approval from U.S. Army Medical Research and Development Command, Office of Human Research Oversight is the last scientific milestone needed for Company to receive
bulk of $13.1 million grant funding
Company anticipates Phase 2 trial to commence by early 2025
CARSON CITY, Nev., Sept. 16, 2024 (GLOBE NEWSWIR...
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long Covid
BioVie Inc - on Track to Receive Additional $12.6 Mln in Grant Funding From U.S. Department of Defense ("Dod") and Initiate Its Phase 2 Trial
No comment yet